A variety of imported products have caused concern and led to lawsuits or received significant attention and may generate litigation, including those addressed below.
Chinese Drywall
Complaints generally allege that the Chinese drywall off-gassed excessive levels of sulfur, a tendency that is particularly prone to happen in warmer, more humid climates. The compounds are alleged to cause odors and corrode copper wiring, which is an element that is critical to the safe functioning of electrical wiring and appliances, particularly air conditioners. Homeowners alleged that the sulfur compounds emitted a noxious odor, like rotten eggs, and that the presence of Chinese drywall devalued their homes. Some allegations focus on health concerns. The off‐gassing allegedly caused allergic reactions, coughing, respiratory problems, sinus problems, throat infections, eye irritation, and nosebleeds in individuals living in Chinese-drywalled homes. [MDL-2047 Chinese-Manufactured Drywall Products Liability Litigation (E.D. La.)]
Laminate Flooring
In 2018, flooring distributor Lumber Liquidators agreed to settle, for $36 million, a multidistrict litigation brought in 2015 involving allegations that some of its Chinese-made laminate flooring contained dangerously high levels of formaldehyde, a carcinogen, and was not as durable as promised. The flooring sold by Lumber Liquidators allegedly contained up to seven times the legally allowed amount of formaldehyde, exposure to which can trigger eye, nose and throat irritation, nausea and headaches. [n re: Lumber Liquidators Chinese-Manufactured Laminate Flooring Products Marketing, Sales Practices and Products Liability Litigation, Case No. 1:15-md-02627, and In re: Lumber Liquidators Chinese-Manufactured Laminate Flooring Durability Marketing and Sales Practices Litigation, Case No. 1:16-md-02743 (E.D. Va.)]
Valsartan
In 2018, it was reported that Valsartan, a Chinese-manufactured blood pressure drug sold worldwide may have contained an impurity known as N-nitroso dimethylamine (NDMA) since 2012. NDMA is classified as a probable human carcinogen. The European Medicines Agency (EMA) raised the issue in July 2018 and the U.S. Food and Drug Administration (FDA) took action to recall impacted valsartan-containing medicines. Industry observers have noted that the situation shows how heavily consumers rely on drugs that contain active pharmaceutical ingredients manufactured in China, accordingly, lawmakers have been intensifying the oversight of foreign drug factories.